Effect of carboplatin dose capping on survival in recurrent breast, ovary and head and neck cancers: a single institutional retrospective study

Introduction Carboplatin based regimens are an integral part of chemotherapy regimens for recurrent head and neck cancers (rHNC), triple negative breast cancers (rTNBC) and ovarian cancers (rOC). Dose reduction/capping of carboplatin remains a controversial aspect of such regimens in patients with m...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 2021-10, Vol.88 (4), p.731-740
Main Authors: Roy, Pritha, Biswas, Satadru, Acharyya, Santanu, Dasgupta, Chandan, Dasgupta, Partha
Format: Article
Language:English
Subjects:
Breast cancer
Cancer
Cancer Research
Capping
Carboplatin
Chemotherapy
Creatinine
Head & neck cancer
Malignancy
Medicine
Medicine & Public Health
Oncology
Original Article
Ovarian cancer
Pharmacology/Toxicology
Statistical analysis
Survival
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Carboplatin based regimens are an integral part of chemotherapy regimens for recurrent head and neck cancers (rHNC), triple negative breast cancers (rTNBC) and ovarian cancers (rOC). Dose reduction/capping of carboplatin remains a controversial aspect of such regimens in patients with moderate creatinine clearance (50 ml/min to 125 ml/min), especially in resource limited setting. The authors, therefore, looked into the magnitude of difference in outcome this makes in the above mentioned subsites. Methods This single institutional retrospective study was performed with a total of 120 patients divided equally into Group A (patients receiving capped dose) and Group B (patients receiving uncapped dose). Further matching was performed with respect to age, sex, body surface area, weight, and primary malignancy subsite and baseline creatinine clearance. Patients in Group A had received 450 mg (for AUC 6 regimens) and 150 mg (for AUC 2 regimens) of carboplatin while patients in Group B received the actual calculated dose of carboplatin determined by the Calvert formula. Median progression free survival (mPFS) and median overall survival (mOS) were the co-primary outcome measures. Results At a median follow-up of 24 months, compared to Group A, Group B had a higher mPFS and mOS by 4 months ( p  
ISSN:0344-5704
1432-0843
DOI:10.1007/s00280-021-04323-0